Vaccines, Blood & Biologics
-
CINRYZE
STN: 125267
Proper Name: C1 Esterase Inhibitor (Human)
Tradename: CINRYZE
Manufacturer: Lev Pharmaceuticals, Inc., License #1780
Indication: For routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).
-
Supporting Documents
January 3, 2012 Summary Basis for Regulatory Action - Cinryze (PDF - 153KB)January 9, 2012 Approval Letter-CINRYZE
To include the incorporation of additional safety data from the open-label uncontrolled routine prophylaxis trial protocol LEVP2006-4 (“Change 3” study) into the labeling.October 10, 2008 Approval Letter - CINRYZE
Product is intended for routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE).Summary Basis for Regulatory Action - CINRYZE Approval History, Letters, Reviews and Related Documents - CINRYZE
-
-
Related Information
FDA Online Label Repository
Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.FDA Licenses for Marketing New Therapy for Rare Genetic Disease
Press Release, 10/10/2008
-
Contact FDA
(800) 835-4709
(301) 827-1800
Consumer Affairs Branch (CBER)
Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Food and Drug Administration
1401 Rockville Pike
Suite 200N/HFM-47
Rockville, MD 20852-1448
-
-